Gene Logic, UCB Pharma Expand 1999 Collaboration | GenomeWeb

NEW YORK, Sept. 6 – Gene Logic has licensed a pair of its technology platforms and a set of gene targets to a business unit of Belgian drug company UCB Pharma, the companies said on Thursday.

Under the deal, which broadens an existing collaboration inked in 1999, UCB Research, of Cambridge, Mass., will gain access to the BioExpress Module of Gene Logic’s GeneExpress suite plus the Genesis Enterprise System, according to a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.